Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes - PubMed (original) (raw)
. 2004 Sep;89(9):4649-55.
doi: 10.1210/jc.2004-0224.
Affiliations
- PMID: 15356076
- DOI: 10.1210/jc.2004-0224
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes
Mandeep Bajaj et al. J Clin Endocrinol Metab. 2004 Sep.
Abstract
To investigate the effect of a sustained (7-d) decrease in plasma free fatty acid (FFA) concentration in individuals genetically predisposed to develop type 2 diabetes mellitus (T2DM), we studied the effect of acipimox, a potent inhibitor of lipolysis, on insulin action and adipocytokine concentrations in eight normal glucose-tolerant subjects (aged 40 +/- 4 yr, body mass index 26.5 +/- 0.8 kg/m(2)) with at least two first-degree relatives with T2DM. Subjects received an oral glucose tolerance test (OGTT) and 120 min euglycemic insulin clamp (80 mU/m(2).min) with 3-[(3)H] glucose to quantitate rates of insulin-mediated whole-body glucose disposal (Rd) and endogenous (primarily hepatic) glucose production (EGP) before and after acipimox, 250 mg every 6 h for 7 d. Acipimox significantly reduced fasting plasma FFA (515 +/- 64 to 285 +/- 58 microm, P < 0.05) and mean plasma FFA during the OGTT (263 +/- 32 to 151 +/- 25 microm, P < 0.05); insulin-mediated suppression of plasma FFA concentration during the insulin clamp also was enhanced (162 +/- 18 to 120 +/- 15 microm, P < 0.10). Following acipimox, fasting plasma glucose (5.1 +/- 0.1 vs. 5.2 +/- 0.1 mm) did not change, whereas mean plasma glucose during the OGTT decreased (7.6 +/- 0.5 to 6.9 +/- 0.5 mm, P < 0.01) without change in mean plasma insulin concentration (402 +/- 90 to 444 +/- 102 pmol/liter). After acipimox Rd increased from 5.6 +/- 0.5 to 6.8 +/- 0.5 mg/kg.min (P < 0.01) due to an increase in insulin-stimulated nonoxidative glucose disposal (2.5 +/- 0.4 to 3.5 +/- 0.4 mg/kg.min, P < 0.05). The increment in Rd correlated closely with the decrement in fasting plasma FFA concentration (r = -0.80, P < 0.02). Basal EGP did not change after acipimox (1.9 +/- 0.1 vs. 2.0 +/- 0.1 mg/kg.min), but insulin-mediated suppression of EGP improved (0.22 +/- 0.09 to 0.01 +/- 0.01 mg/kg.min, P < 0.05). EGP during the insulin clamp correlated positively with the fasting plasma FFA concentration (r = 0.49, P = 0.06) and the mean plasma FFA concentration during the insulin clamp (r = 0.52, P < 0.05). Plasma adiponectin (7.1 +/- 1.0 to 7.2 +/- 1.1 microg/ml), resistin (4.0 +/- 0.3 to 3.8 +/- 0.3 ng/ml), IL-6 (1.4 +/- 0.3 to 1.6 +/- 0.4 pg/ml), and TNFalpha (2.3 +/- 0.3 to 2.4 +/- 0.3 pg/ml) did not change after acipimox treatment. We concluded that sustained reduction in plasma FFA concentration in subjects with a strong family history of T2DM increases peripheral (muscle) and hepatic insulin sensitivity without increasing adiponectin levels or altering the secretion of other adipocytokines by the adipocyte. These results suggest that lipotoxicity already is well established in individuals who are genetically predisposed to develop T2DM and that drugs that cause a sustained reduction in the elevated plasma FFA concentration may represent an effective modality for the prevention of T2DM in high-risk, genetically predisposed, normal glucose-tolerant individuals despite the lack of an effect on adipocytokine concentrations.
Similar articles
- Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA. Bajaj M, et al. Diabetes. 2005 Nov;54(11):3148-53. doi: 10.2337/diabetes.54.11.3148. Diabetes. 2005. PMID: 16249438 Clinical Trial. - Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9. doi: 10.1210/jc.2004-0190. J Clin Endocrinol Metab. 2004. PMID: 15356026 Clinical Trial. - Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Cusi K, et al. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1775-81. doi: 10.1152/ajpendo.00624.2006. Epub 2007 Feb 13. Am J Physiol Endocrinol Metab. 2007. PMID: 17299078 Clinical Trial. - Free fatty acids, insulin resistance, and type 2 diabetes mellitus.
Boden G. Boden G. Proc Assoc Am Physicians. 1999 May-Jun;111(3):241-8. doi: 10.1046/j.1525-1381.1999.99220.x. Proc Assoc Am Physicians. 1999. PMID: 10354364 Review. - Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes.
I S Sobczak A, A Blindauer C, J Stewart A. I S Sobczak A, et al. Nutrients. 2019 Aug 28;11(9):2022. doi: 10.3390/nu11092022. Nutrients. 2019. PMID: 31466350 Free PMC article. Review.
Cited by
- Effects of Dietary Carbohydrate Concentration and Glycemic Index on Blood Glucose Variability and Free Fatty Acids in Individuals with Type 1 Diabetes.
Seckiner S, Bas M, Simsir IY, Ozgur S, Akcay Y, Aslan CG, Kucukerdonmez O, Cetinkalp S. Seckiner S, et al. Nutrients. 2024 May 2;16(9):1383. doi: 10.3390/nu16091383. Nutrients. 2024. PMID: 38732629 Free PMC article. Clinical Trial. - The Effects of Ketogenic Diet on Insulin Sensitivity and Weight Loss, Which Came First: The Chicken or the Egg?
Paoli A, Bianco A, Moro T, Mota JF, Coelho-Ravagnani CF. Paoli A, et al. Nutrients. 2023 Jul 12;15(14):3120. doi: 10.3390/nu15143120. Nutrients. 2023. PMID: 37513538 Free PMC article. Review. - Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer.
Alizadeh J, Kavoosi M, Singh N, Lorzadeh S, Ravandi A, Kidane B, Ahmed N, Mraiche F, Mowat MR, Ghavami S. Alizadeh J, et al. Cancers (Basel). 2023 Apr 7;15(8):2195. doi: 10.3390/cancers15082195. Cancers (Basel). 2023. PMID: 37190124 Free PMC article. Review. - Regulation of Insulin Clearance by Non-Esterified Fatty Acids.
Najjar SM, Abdolahipour R, Ghadieh HE, Jahromi MS, Najjar JA, Abuamreh BAM, Zaidi S, Kumarasamy S, Muturi HT. Najjar SM, et al. Biomedicines. 2022 Aug 5;10(8):1899. doi: 10.3390/biomedicines10081899. Biomedicines. 2022. PMID: 36009446 Free PMC article. Review. - Insulin Sensitivity Is Retained in Mice with Endothelial Loss of Carcinoembryonic Antigen Cell Adhesion Molecule 1.
Muturi HT, Khuder SS, Ghadieh HE, Esakov EL, Noh H, Kang H, McInerney MF, Kim JK, Lee AD, Najjar SM. Muturi HT, et al. Cells. 2021 Aug 14;10(8):2093. doi: 10.3390/cells10082093. Cells. 2021. PMID: 34440862 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous